Consumer Reports Negative on Teva Pharma (TEVA), Mylan (MYL) Deal

Consumer Reports is out negative on the potential deal between Mylan (Nasdaq: MYL) and Teva Pharma (NYSE: TEVA).

In part, the report notes that the deal could hand consumers higher prices for generic and specialty drugs.

Teva and Mylan are both trading at or near session lows on Friday.

You May Also Be Interested In

• Paramount seeks $1.88B bond from state AGs to cover costs of WBD merger delay - CNBC
• Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
• OceanaGold to acquire Ausgold in a deal valued at A$776M